In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.

MLA

Chaturvedi, Anuhar, et al. “In Vivo Efficacy of Mutant IDH1 Inhibitor HMS-101 and Structural Resolution of Distinct Binding Site.” Leukemia, vol. 34, no. 2, Feb. 2020, pp. 416–26. EBSCOhost, https://doi.org/10.1038/s41375-019-0582-x.

APA

Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Araujo Cruz, M. M., Kloos, A., Goerlich, K., Schottmann, R., Othman, B., Struys, E. A., Bähre, H., Grote-Koska, D., Brand, K., Ganser, A., Preller, M., & Heuser, M. (2020). In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia, 34(2), 416–426. https://doi.org/10.1038/s41375-019-0582-x

Chicago

Chaturvedi, Anuhar, Ramya Goparaju, Charu Gupta, Julia Weder, Thomas Klünemann, Michelle Maria Araujo Cruz, Arnold Kloos, et al. 2020. “In Vivo Efficacy of Mutant IDH1 Inhibitor HMS-101 and Structural Resolution of Distinct Binding Site.” Leukemia 34 (2): 416–26. doi:10.1038/s41375-019-0582-x.